Alcohol Use Disorder Market to Grow Rapidly at a 13.6% CAGR by 2034 Owing to Rising Disease Prevalence, Significant Advancements in Genetically-targeted Therapies, along with Innovative Treatments such as GLP-1 Receptor Agonists | DelveInsight

Alcohol Use Disorder Market Summary Alcohol Use Disorder Market Summary Discover the new alcohol use disorder treatment @Alcohol Use Disorder Treatment Market Key Factors Driving the Growth of the Alcohol Use Disorder Market  Rising Prevalence of Alcohol Use Disorder Increasing rates of alcohol consumption worldwide, coupled with lifestyle changes and stress-related factors, have led to a growing number of individuals diagnosed with AUD. The 12-month diagnosed prevalent...

LAS VEGAS, 20/11/2025 (informazione.news - comunicati stampa - salute e benessere)

Alcohol Use Disorder Market Summary

Discover the new alcohol use disorder treatment @ Alcohol Use Disorder Treatment Market

Key Factors Driving the Growth of the Alcohol Use Disorder Market 

Rising Prevalence of Alcohol Use Disorder

Increasing rates of alcohol consumption worldwide, coupled with lifestyle changes and stress-related factors, have led to a growing number of individuals diagnosed with AUD. The 12-month diagnosed prevalent cases of alcohol use disorder are expected to reach 39 million by 2034 in the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan]. This rise is primarily driven by increasing work-related stress, lifestyle changes, anxiety, and greater exposure to medications that may lead to dependency.

Growing Awareness and Early Alcohol Use Disorder Diagnosis

Public health campaigns, physician education, and increased awareness about the harmful effects of alcohol abuse are contributing to earlier diagnosis and intervention. As more patients seek treatment, the AUD market growth is positively impacted.

Rising Investment in R&D and Strong Alcohol Use Disorder Pipeline

Pharmaceutical companies are investing heavily in research and development (R&D) to develop novel treatments and combination therapies targeting AUD. The pipeline of AUD possesses few potential drugs. However, there is a positive outlook for the therapeutics market, with expectations of growth. Companies such as AdialPharmaceuticals (AD04), BeckleyPsytech, Atai Life Sciences (BPL-003), MediciNova (MN-166), Imbrium Therapeutics (Sunobinop), and others are actively engaged in mid- and late-stage research and development efforts for AUD.

Rising Focus on Harm Reduction and Personalized Care

Shifts in treatment paradigms toward harm reduction strategies, personalized therapy, and combination approaches (behavioral + pharmacological) are creating new opportunities in the AUD market, encouraging higher adoption of approved therapies.

Alcohol Use Disorder Market Analysis

AUD is a prevalent and complex condition with diverse treatment objectives, including either complete abstinence or harm reduction. Treatment strategies encompass behavioral interventions, such as cognitive-behavioral therapy (CBT), motivational enhancement therapy, and 12-step programs, as well as pharmacological options like disulfiram, naltrexone, and acamprosate. Over the past seven decades, the FDA has approved four medications for AUD: CAMPRAL (acamprosate), ANTABUSE (disulfiram), REVIA (oral naltrexone), and VIVITROL (extended-release injectable naltrexone). Most of these treatments require patients to achieve abstinence before starting therapy. From the 1950s through the early 1990s, pharmacological treatment for alcohol dependence was limited to ANTABUSE, the first FDA-approved AUD medication in 1951, marketed by Odyssey Pharmaceuticals.

In practical clinical settings, SELINCRO has shown advantages over VIVITROL due to its flexible, as-needed dosing, easier integration into primary care, and suitability for non-abstinence-based approaches. By contrast, VIVITROL remains underutilized despite FDA approval, largely because it requires full abstinence, carries high costs, and suffers from limited prescriber engagement.

Despite the availability of effective treatments, AUD continues to be significantly undertreated. A substantial treatment gap exists due to low awareness, insufficient screening, inadequate treatment infrastructure, and persistent stigma. Only a small proportion of patients receive FDA-approved medications, and slow regulatory processes, limited industry investment, and high clinical trial failure rates further impede the development of new therapies.

Alcohol Use Disorder Competitive Landscape

Some of the AUD drugs in clinical trials include AD04 (Adial Pharmaceuticals), Sunobinop (Imbrium Therapeutics [subsidiary of Purdue Pharma]), BPL-003 (Beckley Psytech and Atai Life Sciences), Ibudilast (MediciNova), TMP-301/HTL0014242 (Tempero Bio and Nxera Pharma), Pemvidutide (Altimmune), and others.

AD04 is a genetically targeted therapy under investigation for treating AUD and is currently in a Phase III clinical trial. The therapy targets specific genotypes, which are identified through the company's proprietary companion diagnostic genetic test. According to Adial Pharmaceuticals' annual presentation, the company plans to discuss the study design, protocol, and statistical analysis plan with the FDA on July 29, 2025, with a potential commercial launch of AD04 anticipated by 2027. According to a December 2024 SEC filing, Adial intends to initiate the Phase III trial in the latter half of 2025, complete production of sufficient drug product, and initiate the revalidation of the companion diagnostic for inclusion in the trial.

BPL-003, developed by Beckley Psytech, is a proprietary intranasal 5-MeO-DMT benzoate formulation delivered via a nasal spray device previously used in an approved drug. It is designed to produce rapid and lasting effects from a single dose with minimal clinic time and is being developed for Treatment-Resistant Depression (TRD) and AUD. BPL-003 is protected by composition-of-matter patents in the US, UK, and Europe, with additional claims pending worldwide. A recent open-label Phase IIa trial in patients with moderate-to-severe AUD was completed.

In January 2025, Beckley Psytech reported positive top-line results from the Phase IIa study, showing that BPL-003 produced significant and sustained reductions in alcohol consumption and heavy drinking days (HDDs) for up to three months after a single dose. These results were presented at the 87th Annual Scientific Meeting of the US College on Problems of Drug Dependence (CPDD) in New Orleans from June 14–18, 2025.

The anticipated launch of these emerging therapies is poised to transform the AUD market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the AUD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the alcohol use disorder drugs market @ Alcohol Use Disorder Drugs 

Recent Developments in the Alcohol Use Disorder Market

What is Alcohol Use Disorder?

AUD is a persistent brain disorder characterized by an inability to control alcohol consumption despite negative consequences. Its severity can range widely and is diagnosed using criteria such as cravings, tolerance, and withdrawal symptoms. AUD affects millions worldwide and is more prevalent in men, although its incidence is increasing among women and younger populations. Major risk factors include genetic predisposition, mental health conditions, and early alcohol exposure. The disorder can result in serious health issues, including liver disease, heart problems, and cognitive decline. Treatment typically involves behavioral therapies, medications, and support groups, yet challenges remain in improving diagnostics, offering personalized care, and reducing stigma. Early intervention combined with comprehensive, long-term support can greatly enhance recovery outcomes.

Alcohol Use Disorder Epidemiology Segmentation

The alcohol use disorder epidemiology section provides insights into the historical and current alcohol use disorder patient pool and forecasted trends for the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The alcohol use disorder treatment market report offers epidemiological analysis for the study period 2020–2034 in the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan], segmented into:

Scope of the Alcohol Use Disorder Market Report

Download the report to understand the etiology of alcohol use disorder @ Alcohol Use Disorder 

Table of Contents

Related Reports

Alcohol Use Disorder Clinical Trial Analysis

Alcohol Use Disorder Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key AUD companies, including Adial Pharmaceuticals, Solvonis Therapeutics, MediciNova, Kinnov Therapeutics, Tonix Pharmaceuticals, Afasci Inc., Tempero Bio, Clearmind Medicine, BioCorRx, BioXcel Therapeutics, Kinnov Therapeutics, Biomed Industries, Lophora, among others.

Substance Use Disorder Market

Substance Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SUD companies including BioXcel Therapeutics, NFL Biosciences, STALICLA, Embera NeuroTherapeutics, PleoPharma, Kinnov Therapeutics, Imbrium Therapeutics, Atai Life Sciences, Beckley Psytech, among others.

Cocaine Use Disorder Market

Cocaine Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CUD companies, including STALICLA, Embera NeuroTherapeutics, among others.

Opioid Use Disorder Market

Opioid Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key OUD companies, including Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, Camurus, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

 

View original content:https://www.prnewswire.co.uk/news-releases/alcohol-use-disorder-market-to-grow-rapidly-at-a-13-6-cagr-by-2034-owing-to-rising-disease-prevalence-significant-advancements-in-genetically-targeted-therapies-along-with-innovative-treatments-such-as-glp-1-receptor-agonists--302621241.html